Sermorelin deserves a closer examination

The men’s numbers got younger. Did the men?

The title of the older men’s hormone study sounds almost irresistible: age-related declines, reversed. In 1992, healthy older men received GHRH(1-29), the peptide known as sermorelin, and their growth hormone and IGF-1 rose. At the higher study amount, those measures no longer differed from the young men’s measures.

I credit the experiment with showing that the older pituitary could still respond. To me, rejuvenation asks too much of that result. The study lasted 14 days and measured hormones; it did not establish a longer life, stronger muscles or better everyday health. The jump from those blood samples to an anti-aging reputation is the question that brought me to these papers.

The original experiment is worth more than either a sales pitch or a shrug. The participants, amounts and actual outcomes give a remarkably specific answer to a narrow question. The research page follows that answer before the claims grow around it.

What is sermorelin? A prompt to the pituitary

Sermorelin is a synthetic copy of the first 29 amino acids of the body’s 44-residue growth hormone-releasing hormone, or GHRH. That shorter fragment retains full GHRH activity. Its diagnostic and pediatric treatment history is why I start with the gland rather than the wellness promises.

The sermorelin peptide prompts the pituitary to release its own growth hormone. A drug that prompts secretion is called a secretagogue. Growth hormone then stimulates IGF-1, a growth signal produced mainly by the liver; the body’s feedback controls still influence release. This is a different intervention from supplying growth hormone directly.

To my mind, that mechanism earns curiosity, not an automatic safety verdict. A responsive gland and intact feedback are interesting biological facts. Neither tells me how an adult’s health will fare after prolonged exposure.

A stimulation test isn’t a rejuvenation test

The historical work had something concrete to measure. Sermorelin was used to test the pituitary’s capacity to release growth hormone and to treat children with insufficient growth hormone. In the multicenter pediatric growth trial, first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation.

That result impresses me because the outcome was growth in children who had a growth-hormone deficiency. It does not need to be inflated into a story about all adults. Nor does the drug’s later disappearance erase it: US branded sales ended in 2008 for commercial reasons, not because of a safety or effectiveness ruling. A review of the resulting gap in diagnostic testing records what that loss meant.

The former FDA approval does not make a compounded sermorelin medicine FDA-approved. FDA’s interim Section 503A compounding policy concerns substances and the policy’s conditions. Those are different questions from whether adult anti-aging treatment works.

The persuasive part needs the hardest questions

There is an appealing logic, to my mind, in prompting a hormone system rather than replacing its output. Walker’s argument for that approach makes the physiological case. Blackman’s skeptical editorial on aging treatment challenges the leap to clinical benefit. These editorials offer arguments rather than new trials proving opposite outcomes.

My sympathies lie with the experiment that makes a claim smaller and more exact. The dosage record separates an amount from a volume; the accounts of effects separate anecdotes from clinical results; and the side-effects page examines a children’s infusion study in which the early hormone rise did not last. That last finding complicates the reassuring word natural in a useful way.